$2.23
3.49% today
Nasdaq, Sep 19, 06:17 pm CET
ISIN
US8776191061
Symbol
TSHA
Sector
Industry

Taysha Gene Therapies Inc Stock price

$2.15
-0.09 4.02% 1M
+0.02 0.94% 6M
+0.38 21.47% YTD
-0.95 30.65% 1Y
-16.35 88.38% 3Y
-17.85 89.25% 5Y
-17.85 89.25% 10Y
Nasdaq, Closing price Wed, Sep 18 2024
-0.03 1.38%
ISIN
US8776191061
Symbol
TSHA
Sector
Industry

Key metrics

Market capitalization $440.63m
Enterprise Value $325.16m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 25.26
P/S ratio (TTM) P/S ratio 34.24
P/B ratio (TTM) P/B ratio 3.98
Revenue growth (TTM) Revenue growth 34.05%
Revenue (TTM) Revenue $12.87m
EBIT (operating result TTM) EBIT $-77.06m
Free Cash Flow (TTM) Free Cash Flow $-75.74m
Cash position $173.19m
EPS (TTM) EPS $-0.87
P/E forward negative
P/S forward 52.67
EV/Sales forward 38.87
Short interest 13.94%
Show more

Is Taysha Gene Therapies Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.

Taysha Gene Therapies Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Taysha Gene Therapies Inc forecast:

11x Buy
100%

Analyst Opinions

11 Analysts have issued a Taysha Gene Therapies Inc forecast:

Buy
100%

Financial data from Taysha Gene Therapies Inc

Assets
Dec '23
149 149
Cash 144 144
Claims - -
Inventories - -
Other current assets Other current assets Current assets 4.80 4.80
118 118
Property, plant and equipment 20 20
Financial assets 2.15 2.15
Intangible Assets - -
Other fixed assets Other assets Fixed assets 95 95
Total Assets 267 267
Liabilities
Dec '23
Equity 75 75
192 192
Current liabilities 37 37
Non-current liabilities 155 155
Total Capital 267 267

In millions USD.

Don't miss a Thing! We will send you all news about Taysha Gene Therapies Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Taysha Gene Therapies Inc Stock News

Neutral
GlobeNewsWire
13 days ago
DALLAS, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on September 3, 2024, the Compensation Committee of Taysha's Board of Directors granted one new employee an opt...
Neutral
Seeking Alpha
about one month ago
Taysha Gene Therapies, Inc. (TSHA) Q2 2024 Earnings Call Transcript
Neutral
GlobeNewsWire
about one month ago
Presented cohort one (low dose) data from both trials of TSHA-102 at 2024 IRSF Rett Syndrome Scientific Meeting that demonstrated durable improvements across consistent clinical domains and an encouraging safety profile in adult (up to 52 weeks) and pediatric (up to 22 weeks) patients
More Taysha Gene Therapies Inc News

Company Profile

Taysha Gene Therapies, Inc. engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II on September 20, 2019 and is headquartered in Dallas, TX.

Head office United States
CEO Sean Nolan
Employees 52
Founded 2019
Website www.tayshagtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today